BLACKBERRY Ltd — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BLACKBERRY Ltd filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 28, 2026 | $549.10M | Apr 9, 2026 |
| FY2026 | Feb 28, 2025 | $534.90M | Apr 9, 2026 |
| FY2026 | Feb 29, 2024 | $759.10M | Apr 9, 2026 |
| FY2025 | Feb 28, 2023 | $526.30M | Apr 2, 2025 |
| FY2024 | Feb 28, 2022 | $718.00M | Apr 4, 2024 |
| FY2023 | Feb 28, 2021 | $893.00M | Mar 31, 2023 |
| FY2022 | Feb 29, 2020 | $1.04B | Apr 1, 2022 |
| FY2021 | Feb 28, 2019 | $904.00M | Mar 31, 2021 |
| FY2020 | Feb 28, 2018 | $932.00M | Apr 7, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 28, 2026 | $418.20M | Apr 9, 2026 |
| FY2026 | Feb 28, 2025 | $394.90M | Apr 9, 2026 |
| FY2026 | Feb 29, 2024 | $490.70M | Apr 9, 2026 |
| FY2025 | Feb 28, 2023 | $366.60M | Apr 2, 2025 |
| FY2024 | Feb 28, 2022 | $467.00M | Apr 4, 2024 |
| FY2023 | Feb 28, 2021 | $643.00M | Mar 31, 2023 |
| FY2022 | Feb 29, 2020 | $763.00M | Apr 1, 2022 |
| FY2021 | Feb 28, 2019 | $698.00M | Mar 31, 2021 |
| FY2020 | Feb 28, 2018 | $670.00M | Apr 7, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 28, 2026 | $53.20M | Apr 9, 2026 |
| FY2026 | Feb 28, 2025 | ($79.00M) | Apr 9, 2026 |
| FY2026 | Feb 29, 2024 | ($130.20M) | Apr 9, 2026 |
| FY2025 | Feb 28, 2023 | ($734.40M) | Apr 2, 2025 |
| FY2024 | Feb 28, 2022 | $12.00M | Apr 4, 2024 |
| FY2023 | Feb 28, 2021 | ($1.10B) | Mar 31, 2023 |
| FY2022 | Feb 29, 2020 | ($152.00M) | Apr 1, 2022 |
| FY2021 | Feb 28, 2019 | $93.00M | Mar 31, 2021 |
| FY2020 | Feb 28, 2018 | $405.00M | Apr 7, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 28, 2026 | $48.30M | Apr 9, 2026 |
| FY2026 | Feb 28, 2025 | $800.0K | Apr 9, 2026 |
| FY2026 | Feb 29, 2024 | $11.00M | Apr 9, 2026 |
| FY2025 | Feb 28, 2023 | ($206.80M) | Apr 2, 2025 |
| FY2024 | Feb 28, 2022 | ($2.00M) | Apr 4, 2024 |
| FY2023 | Feb 28, 2021 | ($1.11B) | Mar 31, 2023 |
| FY2022 | Feb 29, 2020 | ($149.00M) | Apr 1, 2022 |
| FY2021 | Feb 28, 2019 | $60.00M | Mar 31, 2021 |
| FY2020 | Feb 28, 2018 | $283.00M | Apr 7, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 28, 2026 | $113.60M | Apr 9, 2026 |
| FY2026 | Feb 28, 2025 | $108.80M | Apr 9, 2026 |
| FY2026 | Feb 29, 2024 | $127.10M | Apr 9, 2026 |
| FY2025 | Feb 28, 2023 | $134.20M | Apr 2, 2025 |
| FY2024 | Feb 28, 2022 | $219.00M | Apr 4, 2024 |
| FY2023 | Feb 28, 2021 | $215.00M | Mar 31, 2023 |
| FY2022 | Feb 29, 2020 | $259.00M | Apr 1, 2022 |
| FY2021 | Feb 28, 2019 | $219.00M | Mar 31, 2021 |
| FY2020 | Feb 28, 2018 | $239.00M | Apr 7, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Feb 28, 2023 | $340.00M | Mar 31, 2023 |
| FY2023 | Feb 28, 2022 | $297.00M | Mar 31, 2023 |
| FY2023 | Feb 28, 2021 | $344.00M | Mar 31, 2023 |
| FY2022 | Feb 29, 2020 | $493.00M | Apr 1, 2022 |
| FY2021 | Feb 28, 2019 | $409.00M | Mar 31, 2021 |
| FY2020 | Feb 28, 2018 | $476.00M | Apr 7, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 28, 2026 | $50.30M | Apr 9, 2026 |
| FY2026 | Feb 28, 2025 | $16.50M | Apr 9, 2026 |
| FY2026 | Feb 29, 2024 | ($3.50M) | Apr 9, 2026 |
| FY2025 | Feb 28, 2023 | ($262.20M) | Apr 2, 2025 |
| FY2024 | Feb 28, 2022 | ($28.00M) | Apr 4, 2024 |
| FY2023 | Feb 28, 2021 | $82.00M | Mar 31, 2023 |
| FY2022 | Feb 29, 2020 | $26.00M | Apr 1, 2022 |
| FY2021 | Feb 28, 2019 | $100.00M | Mar 31, 2021 |
| FY2020 | Feb 28, 2018 | $704.00M | Apr 7, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 28, 2026 | $3.80M | Apr 9, 2026 |
| FY2026 | Feb 28, 2025 | $3.10M | Apr 9, 2026 |
| FY2026 | Feb 29, 2024 | $7.10M | Apr 9, 2026 |
| FY2025 | Feb 28, 2023 | $7.30M | Apr 2, 2025 |
| FY2024 | Feb 28, 2022 | $8.00M | Apr 4, 2024 |
| FY2023 | Feb 28, 2021 | $8.00M | Mar 31, 2023 |
| FY2022 | Feb 29, 2020 | $12.00M | Apr 1, 2022 |
| FY2021 | Feb 28, 2019 | $17.00M | Mar 31, 2021 |
| FY2020 | Feb 28, 2018 | $15.00M | Apr 7, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 28, 2026 | $1.25B | Apr 9, 2026 |
| FY2026 | Feb 28, 2025 | $1.30B | Apr 9, 2026 |
| FY2025 | Feb 29, 2024 | $1.40B | Apr 2, 2025 |
| FY2024 | Feb 28, 2023 | $1.68B | Apr 4, 2024 |
| FY2023 | Feb 28, 2022 | $2.57B | Mar 31, 2023 |
| FY2022 | Feb 28, 2021 | $2.82B | Apr 1, 2022 |
| FY2021 | Feb 29, 2020 | $3.89B | Mar 31, 2021 |
| FY2020 | Feb 28, 2019 | $3.97B | Apr 7, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 28, 2026 | $499.20M | Apr 9, 2026 |
| FY2026 | Feb 28, 2025 | $575.70M | Apr 9, 2026 |
| FY2025 | Feb 29, 2024 | $619.90M | Apr 2, 2025 |
| FY2024 | Feb 28, 2023 | $822.00M | Apr 4, 2024 |
| FY2023 | Feb 28, 2022 | $1.01B | Mar 31, 2023 |
| FY2022 | Feb 28, 2021 | $1.31B | Apr 1, 2022 |
| FY2021 | Feb 29, 2020 | $1.36B | Mar 31, 2021 |
| FY2020 | Feb 28, 2019 | $1.33B | Apr 7, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 28, 2026 | $746.00M | Apr 9, 2026 |
| FY2026 | Feb 28, 2025 | $719.90M | Apr 9, 2026 |
| FY2026 | Feb 29, 2024 | $775.10M | Apr 9, 2026 |
| FY2026 | Feb 28, 2023 | $856.80M | Apr 9, 2026 |
| FY2025 | Feb 28, 2022 | $1.56B | Apr 2, 2025 |
| FY2024 | Feb 28, 2021 | $1.50B | Apr 4, 2024 |
| FY2023 | Feb 29, 2020 | $2.53B | Mar 31, 2023 |
| FY2022 | Feb 28, 2019 | $2.64B | Apr 1, 2022 |
| FY2021 | Feb 28, 2018 | $2.51B | Mar 31, 2021 |
| FY2020 | Feb 28, 2017 | $2.06B | Apr 7, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 28, 2026 | $479.10M | Apr 9, 2026 |
| FY2026 | Feb 28, 2025 | $472.40M | Apr 9, 2026 |
| FY2026 | Feb 29, 2024 | $474.50M | Apr 9, 2026 |
| FY2025 | Feb 28, 2023 | $489.00M | Apr 2, 2025 |
| FY2024 | Feb 28, 2022 | $844.00M | Apr 4, 2024 |
| FY2024 | Feb 28, 2021 | $849.00M | Apr 4, 2024 |
| FY2023 | Feb 29, 2020 | $1.44B | Mar 31, 2023 |
| FY2022 | Feb 28, 2019 | $1.46B | Apr 1, 2022 |
| FY2021 | Feb 28, 2018 | $569.00M | Mar 31, 2021 |
| FY2020 | Feb 28, 2017 | $559.00M | Apr 7, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 28, 2026 | ($2.17B) | Apr 9, 2026 |
| FY2026 | Feb 28, 2025 | ($2.24B) | Apr 9, 2026 |
| FY2025 | Feb 29, 2024 | ($2.16B) | Apr 2, 2025 |
| FY2024 | Feb 28, 2023 | ($2.03B) | Apr 4, 2024 |
| FY2023 | Feb 28, 2022 | ($1.29B) | Mar 31, 2023 |
| FY2022 | Feb 28, 2021 | ($1.31B) | Apr 1, 2022 |
| FY2021 | Feb 29, 2020 | ($198.00M) | Mar 31, 2021 |
| FY2020 | Feb 28, 2019 | ($32.00M) | Apr 7, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 28, 2026 | $274.70M | Apr 9, 2026 |
| FY2026 | Feb 28, 2025 | $266.70M | Apr 9, 2026 |
| FY2026 | Feb 29, 2024 | $175.10M | Apr 9, 2026 |
| FY2025 | Feb 28, 2023 | $295.70M | Apr 2, 2025 |
| FY2024 | Feb 28, 2022 | $378.00M | Apr 4, 2024 |
| FY2023 | Feb 28, 2021 | $214.00M | Mar 31, 2023 |
| FY2022 | Feb 29, 2020 | $377.00M | Apr 1, 2022 |
| FY2021 | Feb 28, 2019 | $548.00M | Mar 31, 2021 |
| FY2020 | Feb 28, 2018 | $816.00M | Apr 7, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 28, 2026 | $196.50M | Apr 9, 2026 |
| FY2026 | Feb 28, 2025 | $195.30M | Apr 9, 2026 |
| FY2025 | Feb 29, 2024 | $194.10M | Apr 2, 2025 |
| FY2024 | Feb 28, 2023 | $0 | Apr 4, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 28, 2026 | 0 | Apr 9, 2026 |
| FY2026 | Feb 28, 2025 | 0 | Apr 9, 2026 |
| FY2026 | Feb 29, 2024 | 0 | Apr 9, 2026 |
| FY2025 | Feb 28, 2023 | (1) | Apr 2, 2025 |
| FY2024 | Feb 28, 2022 | 0 | Apr 4, 2024 |
| FY2023 | Feb 28, 2021 | (1) | Mar 31, 2023 |
| FY2022 | Feb 29, 2020 | 0 | Apr 1, 2022 |
| FY2021 | Feb 28, 2019 | 0 | Mar 31, 2021 |
| FY2020 | Feb 28, 2018 | 0 | Apr 7, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 28, 2026 | 0 | Apr 9, 2026 |
| FY2026 | Feb 28, 2025 | 0 | Apr 9, 2026 |
| FY2026 | Feb 29, 2024 | 0 | Apr 9, 2026 |
| FY2025 | Feb 28, 2023 | (1) | Apr 2, 2025 |
| FY2024 | Feb 28, 2022 | 0 | Apr 4, 2024 |
| FY2023 | Feb 28, 2021 | (1) | Mar 31, 2023 |
| FY2022 | Feb 29, 2020 | 0 | Apr 1, 2022 |
| FY2021 | Feb 28, 2019 | 0 | Mar 31, 2021 |
| FY2020 | Feb 28, 2018 | 0 | Apr 7, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Feb 28, 2026 | 587.43M | Apr 9, 2026 |
| FY2026 | Feb 28, 2025 | 596.23M | Apr 9, 2026 |
| FY2025 | Feb 29, 2024 | 589.23M | Apr 2, 2025 |
| FY2024 | Feb 28, 2023 | 582.16M | Apr 4, 2024 |
| FY2023 | Feb 28, 2022 | 576.23M | Mar 31, 2023 |
| FY2022 | Feb 28, 2021 | 565.51M | Apr 1, 2022 |
| FY2021 | Feb 29, 2020 | 554.20M | Mar 31, 2021 |
| FY2020 | Feb 28, 2019 | 547.36M | Apr 7, 2020 |